The specialty pharmaceutical sector is one of the most vibrant and promising in all of healthcare. The emphasis by “Big Pharma” on blockbuster drugs has meant that there are many high-quality, FDA-approved pharmaceuticals that do not receive adequate resources to reach their entire patient audience. Specialty pharmaceutical companies provide a platform for these important therapies by focusing on market niches and specific therapeutic categories.
MedPointe seeks to capitalize aggressively on these opportunities through product acquisitions, co-promotion, joint ventures, licensing and other partnership arrangements, especially in the areas of:
- Allergy/Respiratory
- CNS/Neurology/Epilepsy
- Cough/Cold
MedPointe is actively exploring opportunities to enter other niche markets effectively served by a specialty sales force, such as dermatology and ophthalmology. The company’s 465-territory sales and marketing force provides a knowledgeable and trusted link to physicians and healthcare providers across America, and MedPointe’s senior management team is drawn from some of the world’s leading pharmaceutical and health-care organizations. From these foundations, MedPointe is building a world-class specialty pharmaceuticals company.